Orelabrutinib

DB16272InvestigationalSmall molecule

Orelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).

Mechanism: Pharmacologically active on Tyrosine-protein kinase BTK
Curator reviewed
Formula / weight: C₂₆H₂₅N₃O₃ · 427.504 g/mol (avg)
Also known as: obutinib
Code names: ICP-022

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyMZPVEMOYADUARK-UHFFFAOYSA-NSMILESNC(=O)C1=CC=C(N=C1C1=CC=C(OC2=CC=CC=C2)C=C1)C1CCN(CC1)C(=O)C=C

Targets

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

96Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 4 drug categories

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Orelabrutinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.